PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lypova, Nadiia, Dougherty, Susan M., Lanceta, Lilibeth, Chesney, Jason, Imbert-Fernandez, Yoannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307619/
https://www.ncbi.nlm.nih.gov/pubmed/34359849
http://dx.doi.org/10.3390/cells10071679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307619/
https://www.ncbi.nlm.nih.gov/pubmed/34359849
http://dx.doi.org/10.3390/cells10071679

Ejemplares similares